AzTrials
AzTrials

HealthCompProteinNCT06781723

Improving the Anabolic Action of Plant-based Foods Using Complementary Proteins

A study testing Resistance Exercise, Isolated Mixture and Rice and Beans in people with Health and Recreational Activities, run by University of Illinois at Urbana-Champaign at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 246 g of rice and beans or its constituent macronutrients as isolated amino acids, carbohydrates, fiber, and… Read more about this study

Who is it for?
Ages 20 to 35 yearsHealthy volunteers can take part
What is being tested?
Resistance Exercise, Isolated Mixture and Rice and Beans
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11 participants
Where
1 siteUnited States
Study dates
5 Sep 2024to 1 Apr 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 35 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age 20-35 yrs
  • Pre-menopausal
  • Recreationally-active
  • Weight stable for prior 6 months

Who cannot join

  • Age outside of range (20 - 35 yrs)
  • Pregnancy
  • Irregular menstrual cycles (i.e., ~21 day or ~35 day cycle)
  • Participation in previous research using [13C6]phenylalanine
  • Participation in other ongoing research that interferes with this study (e.g., conflicting diet, activity interventions, etc.)
  • Any hospitalization or surgery for a metabolic, cardiovascular, or neuromusculoskeletal complication within the past year
Show all 27Show fewer
  • Allergy or hypersensitivity to local anesthetics, latex, or adhesives (bandages, medical tape, etc.)
  • Excess scarring after injury
  • History of excess bleeding after cut
  • Chronic or frequent dizziness/fainting, and arm or leg weakness/numbness
  • Arthritis
  • Tumors
  • Mental Illness
  • Hepatorenal, cardiovascular musculoskeletal, autoimmune, or neurological disease or disorder
  • Predisposition to hypertrophic scarring or keloid formation
  • Physical activity limitations
  • Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  • Consumption of thyroid, androgenic, or other medications known to affect endocrine function
  • Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
  • Unwillingness to comply with study procedures
  • Weight unstable (variation >5% of bodyweight in last 6-12 months)
  • Current or previous tobacco use with last 6 months
  • Obesity (body mass index; BMI >>30 kg∙m^-2)
  • Score of less than 14 on the Godin-Shephard Leisure-Time Physical Activity Questionnaire
  • Phenylketonuria
  • Anyone hospitalized previously for COVID-19 without a cardiovascular workup screening for cardiovascular issues post-infection
  • Anyone recovering from COVID-19 infection within the preceding 10 days

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Louise Freer Hall

    Urbana, Illinois, 61801

Other trials in United States

About this study

In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 246 g of rice and beans or its constituent macronutrients as isolated amino acids, carbohydrates, fiber, and fat. Repeated blood and muscle biopsies will be collected to determine amino acid concentrations, anabolic signaling and myofibrillar protein synthesis rates during the trials.

Read the detailed description
  1. Preliminary Testing Preparation: Participants will arrive for the preliminary testing session after an overnight fast (~10 h no caloric foods/beverages consumed) and having refrained from exercise for the 72 h prior. Prior to any in-person procedures, participants will be briefed on the procedures and risks associated with participation via reviewing the informed consent document. Participants will be encouraged to ask questions and have their questions answered prior to being asked if they'd like to continue. Confirmation will be documented via signature on an informed consent process form. 1.1 Anthropometrics: Upon provision of consent, participants' height and weight will be measured to confirm body mass index (BMI) is within eligibility limits (18.5 - 30 kg/m^2). Since participants have already been assessed for all other inclusion and exclusion criteria, an eligible BMI will result in study inclusion and continuation of the preliminary testing session. Following confirmation of study eligibility, blood pressure will be measured by a trained member of the research team. Subsequently, body composition will be determined via dual energy x-ray absorptiometry (DEXA) in accordance with manufacturer recommendations. Briefly, participants will be asked to remove all metal objects from their person prior to being positioned by a trained technician for accurate measurement of lean body mass and fat mass. The scan lasts approximately 6-10 minutes during which the participant will be instructed to remain motionless. 1.2 Resting Metabolic Rate: Resting metabolic rate (RMR) will be assessed via indirect calorimetry. This is a non-exertional test whereby RMR is measured using an automated gas analysis system. This device measures oxygen consumption and carbon dioxide production as the difference between inspired and expired gas concentrations. Prior to the beginning of the test, participants will lie supine on a table and a clear, hard plastic hood and soft, clear plastic drape will be placed over the participants neck, head, and shoulders to capture expired gases. Participants will then lie motionless without falling asleep while respiratory gas concentrations are captured. Testing will conclude when RMR is stable for at least 20 min (typically ~30 min from the onset). 1.3 Ten-Repetition Maximum (10RM) Testing: Following resting metabolic rate testing, participants will have their 10RM tested for the leg extension and leg press. To begin, participants will cycle at a self-selected pace on a standard cycle ergometer for ~5 minutes. Participants will then complete a set of 8-10 repetitions at ~50% of their predicted 10RM followed by 1-2 minutes of rest. The load will then be set at ~90% of their predicted 10RM. Load will be increased by 2.5-5.0% following each successful attempt until failure (typically within 5 attempts). Two minutes of rest will be allotted between maximal attempts and 5 minutes between exercises. Leg extension will be tested first followed by leg press. Before leaving the laboratory, participants will be allowed to ask any questions they have before concluding the session. 1.4 Habitual Diet Record: Current diet intake will be assessed through an online automated self-administered (ASA24) diet record system. Participants will receive their individual and private username and password. They will be asked to record 3 consecutive days (2 weekdays, 1 weekend day). As it is an online system, they can complete off-site, at their leisure. 1.5 Planning: Prior to leaving the laboratory, participants and the research team will identify a date for the first infusion trial (at least 7 days following preliminary testing). Moreover, the research team will provide participants with a standardized meal to consume the night before the first infusion and instructions to refrain from strenuous exercise and alcohol consumption for 72 and 24 hours leading into the first trial. Participants will also be offered a snack prior to leaving the laboratory.
  2. Infusion Trials

2.1 Preparation: At least 7 days following preliminary testing or the previous infusion, participants will be asked to return to the laboratory for an infusion trial. On the morning of each infusion, participants will arrive to the laboratory in the morning following an overnight (~10 h no caloric foods/beverages consumed) fast and having refrained from strenuous exercise and alcohol consumption for 72 and 24 hours, respectively. For 3 days preceding each trial, participants will be asked to record their dietary intakes via and online automated self-administered (24 hour) dietary record system (ASA24).

2.2 Stable Isotope Infusion: Upon arrival to the laboratory, participants will lay supine on a clinic-style bed before having an intravenous catheter placed into a dorsal hand or arm vein. No more than four attempts will be made to set the catheter. Following baseline blood sampling, a priming dose of L-[ring-13C6]phenylalanine (2 μmol/kg) will be administered prior to initiation of a constant infusion (0.05 μmol/kg/min) using a calibrated infusion pump. The stable isotope amino acid tracers applied in this experiment are not radioactive and are completely safe. These stable isotopes will enrich the amino acid pool in the body allowing us to identify the rate of incorporation of amino acids into the tissues. The preparation of the tracers for intravenous administration will occur in a sterile environment under a laminar flow hood dedicated to the preparation of tracers and in accordance with Good Manufacturing Practices guidelines.

2.3 Blood Collection: Following initiation of the infusion, a second intravenous catheter will be placed in the contralateral side in a hand or arm vein for repeat blood sampling. Blood samples will be collected will be collected 12 times during the first infusion and 10 times during the second infusion. At time points that coincide with biopsy times (-150, -30 and 300 min), ~16 mL will be collected (7 mL plasma, 7 mL serum, and ~2 mL waste). At all other time points (-210, -90, 0, 30, 60, 90, 120, 180, and 240 min) ~9 mL will be collected (7 mL plasma and ~2 mL waste). Thus, the total volume collected during the first infusion and second infusion will be ~129 mL and ~104 mL, respectively. Blood will be collected into evacuated tubes using Leur-Lok access device connected to a 4-way stopcock. Between draws, the catheter will be kept patent using a saline drip at a low rate (~60 cc/hr).

2.4 Muscle Collection: A total of five muscle biopsies will be collected (three as a part of 1st infusion and two during 2nd infusion). The biopsy procedure involves removal of a small piece of muscle tissue using a sterile hollow needle (Bergström needle) and will be performed by Dr. Nicholas Burd under the auspices of Dr. Jared Willard, MD. Participants will rest on a bed and the area for the biopsy will be shaved, if required. Subsequently, the area will be sterilized using 4% chlorhexidine gluconate before 5 mL of local anesthetic (2% Xylocaine with 1:100,000 epinephrine) is injected subcutaneously with special care to avoid infiltrating the muscle. Once the anesthetic is active (~10 min), Dr. Burd will make a small incision (~4-5 mm) in the skin in order to create an opening through which to put the biopsy needle for tissue collection. Dr. Burd will quickly cut of a small piece of muscle (~50- 100 mg; about the size of a standard pencil eraser) and remove the needle from the subject's leg. During the sample collection (~30 sec), the subjects may feel a sensation of deep pressure in their leg. A sterile disposable drape will be placed under the participant's thigh and sterile gloves will be used for all biopsy procedures.

After the biopsy is completed, a trained research team member will apply pressure with sterile gauze until the bleeding stops (at least 10 min). Subsequently, the incision site will be closed using butterfly stitches (Steri-strips) following by application of a bandage. An elastic pressure wrap will be applied on top of the bandage in order to minimize the chance of bruising. Participants will then be instructed to leave the butterfly stitches and the pressure wrap on the wound for 96 and 24 hrs, respectively.

The participant will be provided with a "biopsy care kit" (described in section 10.1/Biopsy care kit) in order to properly care for the incision after leaving the laboratory. A member of the research team will contact the participants in the day following the trial to check on the healing process.

2.5 Resistance Exercise and Meal Ingestion: Immediately following the closure of the second biopsy in the first infusion trial and after the closure of first biopsy in the second trial participants will begin warming up for an acute bout of resistance exercise. To begin, participants will cycle at a self-selected pace on a standard cycle ergometer for 5 minutes. Subsequently, participants will begin resistance exercise. Participants will complete a warmup set at ~60% of their ten-repetition maximum (10RM) measured at preliminary testing followed by 4 sets of 10-12 repetitions at ~90% 10RM with 1-3 minutes rest between sets for both leg extension and leg press. Participants will match the load, sets, and repetitions from the first infusion during their second trial.

Immediately following the completion exercise, participants will return to the infusion room to consume their meal. During their first infusion, participants will be randomly assigned to consume either 246 g of commercially available rice and black beans (~610 kcal; ~20 g protein, ~127 g of carbohydrate) or isocaloric and isonitrogenous drink of crystallized amino acids and maltodextrin. During their second trial, participants will be randomly assigned to consume the remaining condition.

Commercially-available rice and black beans will be separately cooked and mixed right before consumption on the infusion trial day. The meal will be cooked to an internal temperature of at least 160°F in accordance with the USDA's minimum internal temperature to prevent foodborne illness.

Being tested
Resistance Exercise, Isolated Mixture, Rice and Beans
Keywords
protein, metabolism, plant protein, vegan, protein synthesis, complementary proteins

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Resistance ExerciseBehavioural

    Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.

  • Isolated MixtureDietary supplement

    Also called ISO

    Participants will ingest isolated mixture of crystalized amino acids, maltodextrin, fiber and oil immediately after resistance exercise.

  • Rice and BeansOther

    Participants will ingest cooked rice and beans meal immediately after resistance exercise.

Study groups in NCT06781723
Study groupRoleWhat they receive
Rice and Beans (COMP)ExperimentalRice and Beans After resistance exercise, participants will ingest a meal of 123g Rice, 123g Black Beans (246 g; 575kcal, 20 g Protein, 121 g Carbohydrate, 0.7 g Fat, 1.78 g Fat)
Receives: Behavioral: Resistance Exercise; Other: Rice and Beans
Isolated Nutrients (ISO)Active comparatorThis condition is isonitrogenous and a similar nutrient profile to the experimental complementary mixed meal. The drink is comprised of crystalline amino acids, carbohydrate, fat, and fiber that is matched to rice and beans meal composition.
Receives: Behavioral: Resistance Exercise; Dietary Supplement: Isolated Mixture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Myofibrillar protein fractional synthesis rate

    Myofibrillar protein synthesis rates will be assessed during the postabsorptive and postprandial periods of experimental primed-constant stable isotope infusions.

    Measured: Basal FSR (from -150 to - 30 min), Postprandial FSR (from -30 to 300min)

  2. Plasma Amino Acid Concentrations

    Amino acid concentrations will be assessed in the postabsorptive state (-210, -150, -90, -30, 0 min) and postprandial state (30, 60, 90, 120, 180, 240, 300 min) via LC/MS/MS.

    Measured: Post absorptive (-210, -150, -90, -30, 0 min); Post prandial (30, 60, 90, 120, 180, 240, 300 min)

Secondary outcomes (1)
  1. Activation of Anabolic Signaling Targets

    Phosphorylation of mTOR-dependent anabolic signaling targets will be assessed via Western Blotting (phosphorylated-to-total ratio).

    Measured: -150 min, -30 min, 300 min

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2025
  2. Study start5 Sep 2024
  3. Primary completion1 Apr 2025
  4. Study completion1 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Randomized crossover design
Masking
None (open label)
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06781723
Sponsor's protocol ID
IRB24-0582
Other IDs
7007302
Acronym
CompProtein
Status last verified
May 2025
First submitted
7 Oct 2024
Last updated
8 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Because it is not planned to published in any ICMJE journal.

Publications

  • Zupancic Z, Barnes TM, Deutz MT, Irwin G, Zimring JE, Chen C, Askow AT, Ulanov AV, Willard JW, van Loon LJ, Burd NA. Complementary plant protein pairing does not further increase postexercise myofibrillar protein synthesis after a 20 g protein dose within a high-carbohydrate whole-food matrix in young adults: a randomized controlled trial. Am J Clin Nutr. 2026 May 28:101380. doi: 10.1016/j.ajcnut.2026.101380. Online ahead of print.

    PubMed 42214492

Questions about this trial

What is this clinical trial studying?

A study testing Resistance Exercise, Isolated Mixture and Rice and Beans in people with Health and Recreational Activities, run by University of Illinois at Urbana-Champaign at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Myofibrillar protein fractional synthesis rate (time frame: Basal FSR (from -150 to - 30 min), Postprandial FSR (from -30 to 300min)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06781723, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in